Clinical Trials Logo

Advanced Lung Cancer clinical trials

View clinical trials related to Advanced Lung Cancer.

Filter by:
  • Not yet recruiting  
  • Page 1

NCT ID: NCT06456138 Not yet recruiting - Clinical trials for Advanced Lung Cancer

Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLC

Start date: July 1, 2024
Phase: Phase 1/Phase 2
Study type: Interventional

Lung cancer is the most common cause of cancer-related death worldwide. Approximately 85% to 90% of lung cancer cases are non-small cell lung cancer (NSCLC), of which KRAS is one of the most common driver genes, occurring in 25-30% of lung adenocarcinomas and 3-5% of squamous cell carcinomas. KRAS-mutant NSCLC had been considered undruggable in past decades. This research sought to address a significant challenge in treating NSCLC with KRAS mutations, which are notoriously difficult to target effectively. Here, we proposal that the combined use of anlotinib and trametinib combined with tislelizumab may form an effective strategy for the treatment of KRAS-mutant NSCLC patients.

NCT ID: NCT06107894 Not yet recruiting - Clinical trials for Advanced Breast Cancer

TIL Therapy for Patients With Advanced Solid Tumors

Start date: January 2024
Phase: Phase 1
Study type: Interventional

This study is a phase I clinical trial to investigate the safety and tolerability of NEOG-100 in patients with advanced breast cancer and lung cancer. NEOG-100, an autologous tumor infiltrating lymphocytes (TILs), is infused intravenously into the patient after non-myeloablative (NMA) lymphodepletion treatment.

NCT ID: NCT05431569 Not yet recruiting - Clinical trials for Advanced Lung Cancer

A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer

Start date: July 10, 2022
Phase: Phase 2
Study type: Interventional

A non-randomized, open, Simon'soptimal2-stage study to evaluate the efficacy and safety of 6MW3211 in patients with advanced Lung Cancer who had failed therapy with PD-1/L1 Inhibitor.

NCT ID: NCT05279521 Not yet recruiting - Lung Cancer Clinical Trials

The Effect of Interventional Pulmonary Rehabilitation Exercise With Advanced Lung Cancer.

Start date: March 20, 2022
Phase: N/A
Study type: Interventional

This study concluded that lung rehabilitation exercise programs can improve the psychological distress, self-efficacy, quality of life, six-minute walk distance, muscle strength, and reduce the number of hospitalizations for patients with advanced lung cancer.